Compare · STIM vs SYK
STIM vs SYK
Side-by-side comparison of Neuronetics Inc. (STIM) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STIM and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $122.63B, about 1087.8x STIM ($112.7M).
- Over the past year, STIM is down 57.6% and SYK is down 17.9% - SYK leads by 39.7 points.
- SYK has been more active in the news (5 items in the past 4 weeks vs 4 for STIM).
- SYK has more recent analyst coverage (25 ratings vs 4 for STIM).
- Company
- Neuronetics Inc.
- Stryker Corporation
- Price
- $1.62-9.24%
- $319.74-3.44%
- Market cap
- $112.7M
- $122.63B
- 1M return
- +33.33%
- +2.90%
- 1Y return
- -57.59%
- -17.87%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 4
- 5
- Recent ratings
- 4
- 25
Neuronetics Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest STIM
- Large owner Chernett Jorey bought $62,300 worth of shares (35,000 units at $1.78), increasing direct ownership by 0.33% to 10,588,988 units (SEC Form 4)
- New insider Anderson Cory claimed ownership of 416,812 shares (SEC Form 3)
- Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
- SEC Form 8-K filed by Neuronetics Inc.
- Director Amin Avinash disposed of 42,500 shares, decreasing direct ownership by 59% to 30,000 units (SEC Form 4)
- Large owner Madryn Asset Management, Lp acquired 72,500 shares (SEC Form 4)
- Neuronetics Appoints Robert Greene as Senior Vice President Sales
- SEC Form SD filed by Neuronetics Inc.
- Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 21% to 170,890 units (SEC Form 4)
- Director Muir Glenn P was granted 30,000 shares, increasing direct ownership by 8% to 401,816 units (SEC Form 4)
Latest SYK
- Stryker expands Mako robotics portfolio with full market release of Mako RPS
- BMO Capital Markets initiated coverage on Stryker with a new price target
- Stryker to announce second quarter 2026 financial results
- Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)